Cargando…
Response to imatinib as a function of target kinase expression in recurrent glioblastoma
BACKGROUND: Despite some progress in the treatment of glioblastoma, most patients experience tumor recurrence. Imatinib mesylate, a tyrosine kinase inhibitor of platelet derived growth factor receptor-alpha and -beta, c-fms, c-kit, abl and arg kinase (imatinib targets), has been shown to prevent tum...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320134/ https://www.ncbi.nlm.nih.gov/pubmed/25674429 http://dx.doi.org/10.1186/2193-1801-3-111 |